TOP STORIES
respiratory
ILD

IPF diagnosis and antifibrotic treatment possible without SLB

Antifibrotic therapy can be started in patients with a working diagnosis of idiopathic pulmonary fibrosis (IPF) without requiring surgical lung biopsy (SLB), respiratory physicians say. Their recommendation is based on a review of outcomes of patients who had possible usual interstitial...

Antifibrotic therapy can be started in patients with a working diagnosis of idiopathic pulmonary fibrosis (IPF) without requiring surgical lung...

Read more
Medical politics

Respiratory physician aims to be next AMA president

Queensland respiratory physician Dr Chris Zappala is one of two contenders to be the next president of the Federal AMA. Dr Zappala, who is current vice president of the AMA, is a candidate in the election for national president that will take...

Queensland respiratory physician Dr Chris Zappala is one of two contenders to be the next president of the Federal AMA. Dr Zappala,...
Research

Respiratory journal impact factors revealed

The latest medical journal impact factor rankings have been released, showing that Lancet Respiratory Medicine leads the field in respiratory medicine with an impact factor of 25.094. According to figures released in Clarivate's Journal Citation Reports, other high impact journals...

The latest medical journal impact factor rankings have been released, showing that Lancet Respiratory Medicine leads the field in respiratory...
Lung cancer

Dual immunotherapy approved for NSCLC

The TGA has approved a dual immunotherapy regimen combined with limited chemotherapy for the frontline treatment of some advanced non-small cell lung cancers (NSCLC). The combination of nivolumab (Opdivo), a PD-1 inhibitor, plus ipilimumab (Yervoy), a CTLA-4 inhibitor, with two cycles...

The TGA has approved a dual immunotherapy regimen combined with limited chemotherapy for the frontline treatment of some advanced non-small...